Lind Guro E, Skotheim Rolf I, Lothe Ragnhild A
Department of Cancer Prevention, Rikshospitalet - Radiumhospitalet Medical Centre, Montebello and Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
APMIS. 2007 Oct;115(10):1147-60. doi: 10.1111/j.1600-0463.2007.apm_660.xml.x.
Gene expression is tightly regulated in normal cells, and epigenetic changes disturbing this regulation are a common mechanism in the development of cancer. Testicular germ cell tumor (TGCT) is the most common malignancy among young males and can be classified into two main histological subgroups: seminomas, which are basically devoid of DNA methylation, and nonseminomas, which in general have methylation levels comparable with other tumor tissues, as shown by restriction landmark genome scanning (RLGS). In general, DNA methylation seems to increase with differentiation, and among the nonseminomas, the pluripotent and undifferentiated embryonal carcinomas harbor the lowest levels of DNA promoter hypermethylation, whereas the well-differentiated teratomas display the highest. In this regard, TGCTs resemble the early embryogenesis. So far, only a limited number of tumor suppressor genes have been shown to be inactivated by DNA promoter hypermethylation in more than a minor percentage of TGCTs, including MGMT, SCGB3A1, RASSF1A, HIC1, and PRSS21. In addition, imprinting defects, DNA hypomethylation of testis/cancer associated genes, and the presence of unmethylated XIST are frequent in TGCTs. Aberrant DNA methylation has the potential to improve current diagnostics by noninvasive testing and might also serve as a prognostic marker for treatment response.
基因表达在正常细胞中受到严格调控,而扰乱这种调控的表观遗传变化是癌症发生发展的常见机制。睾丸生殖细胞肿瘤(TGCT)是年轻男性中最常见的恶性肿瘤,可分为两个主要的组织学亚组:精原细胞瘤,其基本上不存在DNA甲基化;非精原细胞瘤,如限制性地标基因组扫描(RLGS)所示,其甲基化水平通常与其他肿瘤组织相当。一般来说,DNA甲基化似乎随着分化而增加,在非精原细胞瘤中,多能且未分化的胚胎癌DNA启动子高甲基化水平最低,而高分化的畸胎瘤则显示出最高水平。在这方面,TGCT类似于早期胚胎发育。到目前为止,在超过一小部分的TGCT中,只有少数肿瘤抑制基因已被证明因DNA启动子高甲基化而失活,包括MGMT、SCGB3A1、RASSF1A、HIC1和PRSS21。此外,印记缺陷、睾丸/癌症相关基因的DNA低甲基化以及未甲基化的XIST在TGCT中很常见。异常DNA甲基化有可能通过非侵入性检测改善当前的诊断,也可能作为治疗反应的预后标志物。